{
  "analysis_date": "2025-08-16",
  "total_papers_with_ae_data": 3,
  "total_patients": 59,
  "adverse_events": {
    "myelosuppression": {
      "papers": 1,
      "patients": 5,
      "paper_percentage": 33.3,
      "patient_percentage": 8.5,
      "pmids": ["2052066"],
      "description": "Myelosuppression (in all 5 patients, requiring dose reduction in 2)"
    },
    "gastrointestinal": {
      "papers": 1,
      "patients": 5,
      "paper_percentage": 33.3,
      "patient_percentage": 8.5,
      "pmids": ["2052066"],
      "description": "Mild gastrointestinal symptoms"
    },
    "fatigue": {
      "papers": 1,
      "patients": 5,
      "paper_percentage": 33.3,
      "patient_percentage": 8.5,
      "pmids": ["2052066"],
      "description": "Fatigue"
    },
    "alopecia": {
      "papers": 1,
      "patients": 53,
      "paper_percentage": 33.3,
      "patient_percentage": 89.8,
      "pmids": ["8839839"],
      "description": "Alopecia 3% (vs 20% in VP16 arm)"
    },
    "pneumonitis": {
      "papers": 1,
      "patients": 1,
      "paper_percentage": 33.3,
      "patient_percentage": 1.7,
      "pmids": ["26666606"],
      "description": "Interstitial pneumonitis, respiratory failure"
    }
  },
  "summary": {
    "most_common_ae": "Alopecia (89.8% of patients)",
    "most_frequent_ae": "Myelosuppression, Gastrointestinal, Fatigue (33.3% of papers each)",
    "serious_ae": "Pneumonitis (rare, 1.7% of patients)",
    "dose_modifications": "Myelosuppression requiring dose reduction in 40% of affected patients"
  }
}
